Investment analysts at The Goldman Sachs Group assumed coverage on shares of Afya (NASDAQ:AFYA – Get Free Report) in a research note issued on Tuesday,Briefing.com Automated Import reports. The firm set a “sell” rating and a $16.00 price target on the stock. The Goldman Sachs Group’s price objective points to a potential downside of 3.56% from the company’s previous close.
Separately, UBS Group began coverage on shares of Afya in a research note on Friday, August 30th. They set a “neutral” rating and a $19.50 price target on the stock.
Check Out Our Latest Report on Afya
Afya Stock Performance
Institutional Trading of Afya
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Marshall Wace LLP grew its holdings in shares of Afya by 41.8% during the second quarter. Marshall Wace LLP now owns 336,985 shares of the company’s stock worth $5,948,000 after purchasing an additional 99,416 shares during the last quarter. Millennium Management LLC increased its holdings in Afya by 45.0% in the second quarter. Millennium Management LLC now owns 291,164 shares of the company’s stock valued at $5,139,000 after purchasing an additional 90,383 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Afya by 19.7% in the second quarter. Renaissance Technologies LLC now owns 266,500 shares of the company’s stock valued at $4,704,000 after buying an additional 43,800 shares during the period. State Street Corp grew its position in shares of Afya by 118.2% during the 3rd quarter. State Street Corp now owns 73,098 shares of the company’s stock worth $1,248,000 after buying an additional 39,592 shares during the period. Finally, Point72 Asset Management L.P. bought a new position in Afya during the 3rd quarter worth approximately $842,000. 88.02% of the stock is currently owned by institutional investors and hedge funds.
About Afya
Afya Limited, through its subsidiaries, operates as a medical education group in Brazil. The company operates through three segments: Undergrad, Continuing Education, and Digital Services. It offers educational products and services, including medical schools, medical residency preparatory courses, graduate courses, and other programs to lifelong medical learners enrolled across its distribution network, as well as to third-party medical schools.
Further Reading
- Five stocks we like better than Afya
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- 3 Hot Buyback Announcements That Will Drive Value in 2025
- The 3 Best Fintech Stocks to Buy Now
- Can HPE Keep Rising Through 2025? The U.S. Government May Decide
- How to Invest in the Best Canadian StocksĀ
- Quantum Computing Stocks Are on Fire: 3 Stocks to Watch
Receive News & Ratings for Afya Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Afya and related companies with MarketBeat.com's FREE daily email newsletter.